You are here

Articles

Posted on Monday, September 21, 2015 - 11:46pm
CDF Issues: Government responds to Cancer Drugs Fund Petition on Blood Cancers
Nature magazine logo
Posted on Wednesday, September 16, 2015 - 12:59pm
Whether cancer is maintained by a small number of stem cells or is composed of proliferating cells with approximate phenotypic equivalency is a central question in cancer biology1.
Posted on Tuesday, August 4, 2015 - 7:29pm
Nature: International Weekly Journal of Science
Leukaemia magazine logo
Posted on Wednesday, July 29, 2015 - 1:22pm
BCR-ABL1 mutations are a common, well-characterized mechanism of resistance to imatinib as first-line treatment of chronic myeloid leukemia in chronic phase (CML-CP).
Posted on Monday, July 27, 2015 - 8:44pm
July 10, 2015 | Chronic Myeloid Leukemia, Hematologic Malignancies, Leukemia & Lymphoma Patients with chronic myeloid leukemia (CML) undergoing treatment with dasatinib had a narrower spectrum of mutations in BCR-...
Posted on Monday, July 27, 2015 - 8:39pm
Abstract Nilotinib is a second-generation tyrosine kinase inhibitors that has been approved for the first-line treatment of chronic phase chronic myeloid leukemia, based on the results of a prospective randomized study...
Posted on Monday, July 20, 2015 - 6:34pm
Naoto Takahashi* Department of Hematology, Nephrology, and Rheumatology, Akita University, Japan Published: 08 July 2014 ABBREVIATIONS: CML: Chronic Myeloid Leukemia; TKIs: Tyrosine Kinase Inhibitors; CCyR: Complete...
Posted on Friday, July 17, 2015 - 3:09pm
T P Hughes, G Saglio, A Quintás-Cardama, M J Mauro, D-W Kim, J H Lipton, M B Bradley-Garelik, J Ukropec and A Hochhaus BCR-ABL1 mutations are a common, well-characterized mechanism of resistance to imatinib as first-...
Posted on Tuesday, July 7, 2015 - 11:50am
Elisabetta Abruzzese, Malgorzata Monika Trawinska, Alessio Pio Perrotti, and Paolo De Fabritiis Abstract The management of patients with chronic myeloid leukemia (CML) during pregnancy has become...
Posted on Monday, June 29, 2015 - 2:50pm
Published in Oncology News · June 12, 2015 June 11, 2015 – Vienna, Austria – A comparison of different first-line treatment strategies for chronic myeloid leukemia in a network meta-analysis has shown a significant and...
Posted on Tuesday, May 26, 2015 - 3:43pm
News | March 17, 2015 | Chronic Myeloid Leukemia, Hematologic Malignancies, Leukemia & Lymphoma By Cancer Network Staff A single-arm, open-label trial in Australia found that selective early switching from imatinib...
Posted on Tuesday, May 26, 2015 - 3:33pm
News | February 17, 2015 | Chronic Myeloid Leukemia, Hematologic Malignancies, Leukemia & Lymphoma By Cancer Network Staff In a paper that shows the benefits of looking at old drugs in new ways, researchers showed...
Posted on Tuesday, May 26, 2015 - 3:25pm
News | April 07, 2015 | Chronic Myeloid Leukemia, Hematologic Malignancies, Leukemia & Lymphoma By Cancer Network Staff Interferon alpha 2a molecule.
Posted on Saturday, May 9, 2015 - 2:23pm
L Kalmanti, S Saussele, M Lauseker, M C Müller, C T Dietz, L Heinrich, B Hanfstein, U Proetel, A Fabarius, S W Krause, S Rinaldetti, J Dengler, C Falge, E Oppliger-Leibundgut, A Burchert, A Neubauer, L Kanz, F...
Posted on Saturday, May 9, 2015 - 2:16pm
N C P Cross1,2, H E White1,2, D Colomer3, H Ehrencrona4, L Foroni5, E Gottardi6, T Lange7, T Lion8, K Machova Polakova9, S Dulucq10, G Martinelli11, E Oppliger Leibundgut12, N Pallisgaard13, G Barbany14, T Sacha15, R...